These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29577495)

  • 1. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.
    Boyd SD; Harrington P; Komatsu TE; Naeger LK; Chan-Tack K; Murray J; Birnkrant D; Struble K
    J Viral Hepat; 2018 Aug; 25(8):969-975. PubMed ID: 29577495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Gilles L; De Locht P; Picchio G; De Meyer S; Sarrazin C
    J Clin Virol; 2015 Nov; 72():133-40. PubMed ID: 26513763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
    J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.
    Zhou S; Qi K; Bersoff-Matcha SJ; Mishra P; Struble K
    J Viral Hepat; 2024 Feb; 31(2):78-87. PubMed ID: 38111976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
    Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
    Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
    J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Gane E; Ben Ari Z; Mollison L; Zuckerman E; Bruck R; Baruch Y; Howe AY; Wahl J; Bhanja S; Hwang P; Zhao Y; Robertson MN
    J Viral Hepat; 2016 Oct; 23(10):789-97. PubMed ID: 27291249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
    Moreno C; Hezode C; Marcellin P; Bourgeois S; Francque S; Samuel D; Zoulim F; Grange JD; Shukla U; Lenz O; Ouwerkerk-Mahadevan S; Fevery B; Peeters M; Beumont M; Jessner W
    J Hepatol; 2015 May; 62(5):1047-55. PubMed ID: 25596313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
    J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
    Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
    Dietz J; Graf C; Berg CP; Port K; Deterding K; Buggisch P; Peiffer KH; Vermehren J; Dultz G; Geier A; Reiter FP; Bruns T; Schattenberg JM; Durmashkina E; Gustot T; Moreno C; Trauth J; Discher T; Fischer J; Berg T; Kremer AE; Müllhaupt B; Zeuzem S; Sarrazin C;
    JHEP Rep; 2024 Jul; 6(7):101072. PubMed ID: 39006503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.